Intravitreal fluocinolone acetonide implant (ILUVIEN®) for the treatment of retinal conditions. A review of clinical studies
No Thumbnail Available
Authors
Mushtaq, Y
Mushtaq, M.M
Gatzioufas, Z
Ripa, M
Motta, L
Panos, G.D
Issue Date
2023
Type
Scientific Paper
Language
Keywords
Research Subject Categories::MEDICINE
Alternative Title
Abstract
Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non-infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
Keywords: Iluvien; diabetic macular oedema; intravitreal implant; posterior uveitis; retinal vein occlusion; steroid implant.
© 2023 Mushtaq et al.
PubMed Disclaimer
Description
Citation
Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies. Drug Des Devel Ther. 2023 Mar 30;17:961-975. doi: 10.2147/DDDT.S403259. PMID: 37020801; PMCID: PMC10069638.